Moderna (MRNA) director vested 1,439 RSUs; ownership 2,019 shares

Insider transaction summary: A Form 4 shows that Hussain Abbas, a director of Moderna, Inc. (MRNA), had 1,439 restricted stock units (RSUs) vest and convert into 1,439 shares of common stock on 10/02/2025.

Rhea-AI Filing Summary

Insider transaction summary: A Form 4 shows that Hussain Abbas, a director of Moderna, Inc. (MRNA), had 1,439 restricted stock units (RSUs) vest and convert into 1,439 shares of common stock on 10/02/2025. After the vesting, he beneficially owned 2,019 shares. The reported RSU conversion carried a price of $0 on the Form, which reflects that the shares resulted from vested awards rather than a purchased transaction. The filing is signed by an attorney-in-fact on 10/06/2025.

Positive

• 1,439 RSUs vested into common stock on 10/02/2025, increasing director alignment with shareholders
• Beneficial ownership rose to 2,019 shares, reflecting direct ownership rather than indirect holdings

Negative

• None.

Insights

Corporate Governance Analyst

Director RSUs vested, modest increase in share ownership.

Vesting of 1,439 RSUs increased the director's direct holdings to 2,019 shares, which is a small but routine ownership change for an executive-level equity award. The filing records conversion at $0, indicating these were compensation awards maturing into common stock rather than purchased shares.

The primary dependency is the company's equity compensation schedule and vesting terms; no sale or purchase occurred here, so there is no immediate liquidity event to monitor. Near-term items to watch are additional filings that show any subsequent sales, option exercises, or changes in beneficial ownership.

Insider Trade Summary

1,439 shares exercised/converted

Exercise 2 txns

Insider Hussain Abbas

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,439	$0.00	$0.00
Exercise	Common Stock	1,439	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 2,019 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units convert into common stock on a one-for-one basis.
2. F2. The shares subject to this restricted stock unit award vested in full on October 2, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Hussain Abbas report on Form 4 for MRNA?

The Form 4 reports that 1,439 restricted stock units vested and converted into 1,439 shares on 10/02/2025, leaving him with 2,019 shares beneficially owned.

Did the director buy or sell shares in this transaction (MRNA)?

No purchase or sale occurred; the Form shows conversion of RSUs with a reported price of $0, indicating vesting of granted awards rather than a market transaction.

When did the filing for the RSU vesting get signed?

The Form 4 was signed by an attorney-in-fact on 10/06/2025.

How many shares does Hussain Abbas own after the reported transaction?

He beneficially owns 2,019 shares following the RSU vesting reported on the Form 4.

What does a reported price of $0 mean on this Form 4?

A $0 price typically indicates the shares were issued upon vesting of equity awards (RSUs) rather than bought in a cash transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hussain Abbas

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		M(1)		1,439	A	(2)	2,019	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/02/2025		M(1)			1,439	(2)	(2)	Common Stock	1,439	$0	0	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. The shares subject to this restricted stock unit award vested in full on October 2, 2025.

	/s/ James Dillon, As Attorney-in-Fact	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.